Evidence map›Paper›PMID 39781629›Full record

ArticleHaematologica2025

High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies.

Yousef Laham, Shimrit Ringelstein-Harlev, Daniel Kurnik, Riva Fineman, Dana Yehudai-Ofir, Lilach Bonstein, Noga Setter-Marco, Eyal Braun, Itai Ghersin, Tsila Zuckerman and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yousef LahamDepartment of Internal Medicine H, Rambam Health Care Campus, Haifa.
Shimrit Ringelstein-HarlevDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa.
Daniel KurnikSection of Clinical Pharmacology and Toxicology, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa.
Riva FinemanDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa.
Dana Yehudai-OfirDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa.
Lilach BonsteinBlood Bank and Platelet Immunology Laboratory, Rambam Health Care Campus, Haifa.
Noga Setter-MarcoDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa.
Eyal BraunDepartment of Internal Medicine H, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa.
Itai GhersinDepartment of Internal Medicine H, Rambam Health Care Campus, Haifa.
Tsila ZuckermanDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa.
Ofrat Beyar-KatzDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa. o_katz@rmc.gov.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39781629
PMCPMC12050934

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.